| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC2131 |
| Trial ID | NCT03999697 |
| Disease | B-Cell Lymphoma | Follicular Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Plasma Cell Neoplasm | Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies |
| Year | 2018 |
| Country | China |
| Company sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Other ID(s) | PG-CART-22-I-001 |
| Cohort 1 | |||||||||||
|
|||||||||||